Anti-PD-1 Therapy with Adjuvant Ablative Fractional Laser Improves Anti-Tumor Response in Basal Cell Carcinomas.
ablative fractional laser
autochthonous cancer model
basal cell carcinoma
immunotherapy
programmed cell death-1 inhibitor
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Dec 2021
16 Dec 2021
Historique:
received:
17
11
2021
revised:
08
12
2021
accepted:
14
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
The efficacy of anti-programmedcelldeath1therapy (aPD-1), which was recently approved for basal cell carcinoma (BCC) treatment, can be enhanced by adjuvant ablative fractional laser (AFL) in syngeneic murine tumor models. In this explorative study, we aimed to assess locally applied AFL as an adjuvant to systemic aPD-1 treatment in a clinically relevant autochthonous BCC model. BCC tumors (
Identifiants
pubmed: 34944945
pii: cancers13246326
doi: 10.3390/cancers13246326
pmc: PMC8699063
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : LEO Foundation
ID : LF18045
Références
Immunol Lett. 2020 Apr;220:88-96
pubmed: 30885690
BMC Genomics. 2014 Mar 13;15:190
pubmed: 24621249
Cancer Res. 2012 Jul 1;72(13):3153-62
pubmed: 22564522
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
Dermatol Ther. 2009 Nov;22 Suppl 1:S8-15
pubmed: 19891690
Lancet Oncol. 2021 Jun;22(6):848-857
pubmed: 34000246
JAMA Dermatol. 2021 May 1;157(5):559-565
pubmed: 33760003
Nat Med. 1999 Nov;5(11):1285-91
pubmed: 10545995
Int J Mol Sci. 2017 Jul 31;18(8):
pubmed: 28788102
Clin Cancer Res. 2018 Nov 1;24(21):5335-5346
pubmed: 30068705
J Immunother Cancer. 2019 Nov 28;7(1):328
pubmed: 31779705
Clin Cancer Res. 2011 May 15;17(10):3378-87
pubmed: 21558397
Lasers Surg Med. 2021 Nov;53(9):1227-1237
pubmed: 33811359
Drugs. 2018 Nov;78(17):1841-1846
pubmed: 30456447
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Cancer Cell. 2011 Jan 18;19(1):114-24
pubmed: 21215705
JAMA Dermatol. 2015 Oct;151(10):1081-6
pubmed: 25928283
J Immunother Cancer. 2016 Nov 15;4:70
pubmed: 27879972
J Cell Mol Med. 2019 Aug;23(8):4854-4865
pubmed: 31210425
Cancer Cell. 2010 Apr 13;17(4):388-99
pubmed: 20385363
Front Immunol. 2018 Nov 09;9:2456
pubmed: 30473691
NPJ Genom Med. 2016;1:
pubmed: 27942391
Cancers (Basel). 2021 Oct 28;13(21):
pubmed: 34771568
Arch Dermatol Res. 2021 Oct 13;:
pubmed: 34647186
Adv Drug Deliv Rev. 2020 Jan 1;153:185-194
pubmed: 31923431
PLoS One. 2014 Jun 06;9(6):e98259
pubmed: 24906014
Clin Oncol (R Coll Radiol). 2019 Nov;31(11):759-768
pubmed: 31522944
PLoS One. 2017 Dec 6;12(12):e0188799
pubmed: 29211768
Sci Transl Med. 2021 Feb 17;13(581):
pubmed: 33597266
JAMA Dermatol. 2017 Apr 1;153(4):285-290
pubmed: 28259105
J Immunother. 2018 Sep;41(7):343-349
pubmed: 29939876
Biomedicines. 2020 Oct 23;8(11):
pubmed: 33113965
Immunol Lett. 2008 Jun 15;118(1):49-54
pubmed: 18400308
J Clin Oncol. 2009 Oct 1;27(28):4709-17
pubmed: 19720929
J Biomed Opt. 2009 Nov-Dec;14(6):064044
pubmed: 20059282
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719
J Skin Cancer. 2012;2012:907543
pubmed: 23024864
J Invest Dermatol. 2020 Oct;140(10):2051-2059
pubmed: 32135181
Dermatol Surg. 2020 Aug;46(8):1045-1053
pubmed: 32049702
Blood. 2017 Apr 6;129(14):1991-2001
pubmed: 28143882
Int J Hyperthermia. 2018 Dec;34(8):1337-1350
pubmed: 29482392
Blood. 2013 Mar 7;121(10):1677-89
pubmed: 23305731
J Immunother Cancer. 2017 Mar 21;5:23
pubmed: 28344809
PLoS One. 2017 Sep 18;12(9):e0184852
pubmed: 28922374
Open Biol. 2018 Jun;8(6):
pubmed: 29875199
J Invest Dermatol. 2017 Dec;137(12):2613-2619
pubmed: 28774592
J Control Release. 2018 Apr 10;275:242-253
pubmed: 29454062
Sci Rep. 2017 Oct 6;7(1):12751
pubmed: 28986576
Immunology. 2000 Dec;101(4):521-30
pubmed: 11122456